Monitoring of CD3+ T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation


ATA P., KARA M., Özdemir E., CANBAKAN M., Gökçe A., Bayraktar F., ...Daha Fazla

Transplantation Proceedings, cilt.45, sa.3, ss.929-931, 2013 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 45 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/j.transproceed.2013.02.092
  • Dergi Adı: Transplantation Proceedings
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.929-931
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Aim: Although antithymocyte globulin (ATG) has been used for years, its ideal dose and administration period is obscure. Herein, we sought to use the CD3+ cell count to detect the optimal ATG dosage. Material and Methods: Twenty-one patients who underwent cadaveric donor renal transplantation from January 2009 to January 2012 received a 1 mg/kg ATG initial dose at the time of the operation. Patients were randomized into 2 cohorts. Group 1 (n = 11) received ATG according to the clinical and total lymphocyte count and group 2 (n = 10), the dose was tailored according to the CD3+ cell count. We compared the total and daily ATG dosages, ATG administration period, side effects of ATG, the number of days to a serum creatinine level <2 mg/dL, graft function at 3 months, acute rejection episodes, infection rates, costs of CD3+ analysis, and ATG amounts. Results: Both groups showed similar gender, age, and human leukocyte antigen matching data. There was no difference in presensitizing events or panel-reactive antibody class 1 and 2 levels. The number of days to a serum creatinine level of <2 mg/dL was 11 ± 1.5 for group 1 versus 10.4 ± 0.8 for group 2 (P =.45). Between groups 1 and 2, there was a significant difference between the mean total (P =.031) and mean daily ATG dosages (P =.006). We used a total dose of 3800 mg ATG for group 1 and 2200 mg for group 2 and for the group 2 who underwent 43 CD3+ cell counts. The expenditure per patient was 20% higher among group 1 than group 2. Conclusion: Determination of appropriate ATG dosages by CD3+ cell counts was useful, reliable, and cost effective. © 2013 Elsevier Inc.